They used MWCNTs as tumor antigen nanocarriers to deliver immunoadjuvants such as cytosine-phosphate-guanine oligodeoxynucleotide (CpG) and anti-CD40 Ig (CD40) with the model antigen ovalbumin (OVA) to elicit an immune response against OVA-expressing tumor cells. The gene discussed is CD40; the disease is neoplasm.